Logo Logo Logo Logo Logo
  • Home
  • Company
    • Company Focus
    • Leadership Team
    • Scientific Advisory Board
    • Calypso Biotech Operations
    • Board of Directors
  • Science
  • Pipeline
  • Newsroom
  • Contact
  • Careers
  • Home
  • Company
    • Company Focus
    • Leadership Team
    • Scientific Advisory Board
    • Calypso Biotech Operations
    • Board of Directors
  • Science
  • Pipeline
  • Newsroom
  • Contact
  • Careers

15 December 2022: Calypso Biotech announces first patient with Eosinophilic Esophagitis dosed in anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 Phase 1a/b Trial, and animal proof of concept data in Atopic Dermatitis.

Posted at h in Press release
Read More

09 September 2021: Calypso Biotech announces first patient with Celiac Disease dosed in anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 Phase 1b Trial, and extension of Series A to €28M

Posted at h in Press release
Read More

16 November 2020: Calypso Biotech announces successful dosing of first Phase 1 cohort with anti-Interleukin-15 (IL-15) monoclonal antibody CALY-002 for the treatment of Autoimmune Diseases

Posted at h in Press release

 

Read More

20 February 2019: Calypso Biotech BV secures 20 Million EUR in Series A Financing and Strengthens Team to Develop Anti-IL-15 Therapeutic Antibody for Autoimmune Diseases.

Posted at h in Press release

Click to see full press release...

Read More

19 February 2019: AGC Biologics A/S and Calypso Biotech BV Announce Agreement for Process Development and cGMP Manufacture of CALY-002

Posted at h in Press release

Click to see full press release...

Read More

31 March 2017: Calypso Biotech licenses CALY-001 best-in-class anti-MMP-9 antibody to EA Pharma

Posted at h in Press release
Calypso Biotech SA announced today that it has entered a global licensing and collaboration agreement with EA Pharma Co., Ltd. to develop CALY-001, a best-in-class anti-MMP-9 fully human monoclonal antibody.
Read More

© Calypso Biotech 2018 – Legal disclaimer